Philip has 24 years of pharmaceutical experience in drug discovery, toxicology, non-clinical and clinical research. Mr. Downing worked for a clinical research lab, GFi Pharmaceuticals (now Covance Labs), as an Analytical Scientist designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies. He also worked at BASi for nearly 20 years, starting as an Analytical Chemist and rapidly moving into influential leadership positions throughout his tenure.
“Philip has demonstrated the ability to cultivate a strong, capable team fostered by a customer-first culture that is driving continued success in top line growth, quality standards and on time delivery. A trusted partner in client relationships, Philip's extensive experience is matched by his judgment, technical capabilities and management skills. Philip’s leadership and guidance during this time of transition for BASi has also been instrumental to the Board and me. His leadership and vision will continue to be an asset to BASi and further support our client’s drug discovery efforts,” said Larry Boulet, BASI chairman of the board. Mr. Downing continues to serve BASi as the acting Principal Executive Officer.